MC4R Agonist

BOSTON — September 22, 2026 Rhythm Pharmaceuticals announced that Health Canada has approved IMCIVREE® (setmelanotide) for weight management in...

BOSTON, August 24, 2026 Rhythm Pharmaceuticals, Inc. announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted...

San Francisco, California, August 12, 2026 Tasman Therapeutics announced a multi-year strategic partnership with Osmind to support the development...

Boston, Massachusetts, August 11, 2026 Rhythm Pharmaceuticals announced that the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA)...

BOSTON, August 4, 2026 Rhythm Pharmaceuticals announced encouraging preliminary Phase 2 clinical trial results for RM-718, its investigational once-weekly...

BOSTON, Mass., July 8, 2026 Rhythm Pharmaceuticals announced that the New England Journal of Medicine (NEJM) has published the...

BOSTON, MA, May 1, 2026 Rhythm Pharmaceuticals, Inc. announced that the European Commission has granted marketing authorization for IMCIVREE®...